California Trim Clinic

Medications offered

As listed on the provider’s own site. Whether a product is FDA-approved or compounded is the single most important distinction here — we explain why.

• Compounded GLP-1 medicationCompounded · not FDA-approved
• Compounded peptide therapyCompounded · not FDA-approved

What they publish

California Trim Clinic publishes 1 of 12 standard terms. Fields marked “not publicly disclosed” were not stated on the pages we captured, and we have not filled those gaps with assumptions. Compare disclosure across providers

Membership / programme fee

Pricing was not published on the page we captured

Medication cost

Not publicly disclosed on the pages we captured.

Introductory offer

Not publicly disclosed on the pages we captured.

Insurance

Not publicly disclosed on the pages we captured.

HSA / FSA

Not publicly disclosed on the pages we captured.

Consultation process

Not publicly disclosed on the pages we captured.

Eligibility

Not publicly disclosed on the pages we captured.

Lab work

Not publicly disclosed on the pages we captured.

Pharmacy fulfilment

Explicitly references 503A compounding pharmacies on its own pages — one of very few providers here to name the facility type at all.

Shipping

Not publicly disclosed on the pages we captured.

Support services

Not publicly disclosed on the pages we captured.

Cancellation

Not publicly disclosed on the pages we captured.

Refunds

Not publicly disclosed on the pages we captured.

What stands out

• Naming 503A compounding pharmacies openly is more disclosure than almost any provider in this directory offers. 503A pharmacies compound per individual prescription and are regulated primarily by state boards rather than inspected by the FDA like 503B outsourcing facilities.
• Offers compounded peptide therapy alongside GLP-1s. Peptides sold outside approved indications are a separate and less regulated category worth treating with caution.
• No pricing published on the page we captured.

Questions to ask before you pay

These are things we could not settle from published pages, or that we think are easy to misread. Get answers in writing.

• Ask which specific 503A pharmacy, and check its state licensure.
• Treat compounded peptide therapy as a distinct decision from GLP-1 treatment, with its own evidence question.
• Establish pricing before starting an intake.